LDE225 + BKM120
Phase 1CompletedDevelopment Stage
Dose Escalation
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Jul 1, 2012 → Apr 1, 2015
About LDE225 + BKM120
LDE225 + BKM120 is a phase 1 stage product being developed by Novartis for Dose Escalation. The current trial status is completed. This product is registered under clinical trial identifier NCT01576666. Target conditions include Dose Escalation, Safety, Preliminary Efficacy.
What happened to similar drugs?
1 of 1 similar drugs in Dose Escalation were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01576666 | Phase 1 | Completed |
Competing Products
6 competing products in Dose Escalation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-2752 + Durvalumab | AstraZeneca | Phase 1 | 29 |
| E3810 + E3810 + Teprenone | Eisai | Phase 2/3 | 38 |
| Rabeprazole + Rabeprazole | Eisai | Phase 2/3 | 38 |
| Carbidopa/levodopa/entacapone | Novartis | Approved | 43 |
| ETC-1002 | Esperion Therapeutics | Phase 1 | 23 |
| AUTO CAR T cell therapy | Autolus Therapeutics | Phase 2 | 32 |